Human FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (SPR & BLI verified), produced by co-expression of FCGRT and B2M, has a calculated MW of 31.2 kDa (FCGRT) and 13.1 kDa (B2M). Subunit FCGRT is fused with a polyhistidine tag at the C-terminus and subunit Beta-2 microglobulin (B2M) is fused with Strep II-tag at the C-terminus. The reducing (R) protein migrates as 33 kDa (FCGRT) and 13 kDa (B2M) respectively due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Human FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (SPR & BLI verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (SPR & BLI verified) (Cat. No. FCM-H5286) on CM5 Chip via Anti-His antibody, can bind Herceptin with an affinity constant of 0.261 μM as determined in a SPR assay (Biacore T200) (QC tested).
Immobilized Human FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (SPR & BLI verified) (Cat. No. FCM-H5286) on CM5 Chip, can bind Herceptin with an affinity constant of 1.19 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Human FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (SPR & BLI verified) (Cat. No. FCM-H5286) on SA Biosensor via Biotin his antibody, can bind Herceptin with an affinity constant of 0.27 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Human FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (SPR & BLI verified) (Cat. No. FCM-H5286) on AR2G Biosensor, can bind Herceptin with an affinity constant of 0.35 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Biotinylated Human Serum Albumin, His,Avitag (Cat. No. HSA-H82E3) on SA Biosensor, can bind Human FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (SPR & BLI verified) (Cat. No. FCM-H5286) with an affinity constant of 0.641 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Authors: Kielau Kisalu, Neville et al.
Journal: JCI Insight 2020
Application: BLI
Engineered antibody Fc variants for enhanced serum half life
Authors: G Georgiou, et al
Journal: US20190048078A1 2019
Application: SPR
Authors: Simonov V, et al
Journal: Biologicals 2019
Application: BLI
Authors: Yang B, et al.
Journal: Biomater Sci 2018
Application: ELISA
Authors: Zhao C, et al.
Journal: Mol Cell Endocrinol 2018
Application: SPR
Authors: Kenniston JA, et al.
Journal: J Biol Chem 2017
Application: ELISA & SPR
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.
A-Z